Published in final edited form as:

Glia. 2008 November 15; 56(15): 1637–1647. doi:10.1002/glia.20716.

E-cadherin expression in postnatal Schwann cells is regulated by the cAMP-dependent protein kinase A pathway

Audrita T. Crawford^{1,2}, Darshan Desai¹, Pradeepa Gokina, Sayantani Basak, and Haesun A. Kim

Department of Biological Sciences, Rutgers University, Newark, NJ 07102

Abstract

Expression of E-cadherin in the peripheral nervous system is a highly regulated process that appears postnatally in concert with the development of myelinating Schwann cell lineage. As a major component of autotypic junctions, E-cadherin plays an important role in maintaining the structural integrity of non-compact myelin regions. *In vivo*, the appearance of E-cadherin in postnatal Schwann cell is accompanied by the disappearance of N-cadherin, suggesting reciprocal regulation of the two cadherins during Schwann cell development. The molecular signal that regulates the cadherin switch in Schwann cell is unclear. Using a neuron-Schwann cell co-culture system, here we show that E-cadherin expression is induced by components on the axonal membrane. We also show that the axonal effect is mediated through cAMP-dependent protein kinase A (cAMP-PKA) activation in the Schwann cell: 1) inhibition of cAMP-PKA blocks axon-induced E-cadherin expression and 2) cAMP elevation in the Schwann cell is sufficient to induce E-cadherin expression. In addition, cAMP-dependent E-cadherin expression is promoted by contact between adjacent Schwann cell membranes, suggesting its role in autotypic junction formation during myelination. Furthermore, cAMP-induced E-cadherin expression is accompanied by suppression of N-cadherin expression. Therefore, we propose that axon-dependent activation of cAMP-PKA serves as a signal that promotes cadherin switch during postnatal development of Schwann cells.

Introduction

The formation of myelin sheath is an essential developmental process that enables rapid propagation of action potentials in the nervous system. During myelination in the peripheral nervous system (PNS), individual Schwann cells repeatedly enwrap single axons, forming multiple concentric membrane layers. The subsequent membrane compaction (exclusion of Schwann cell cytoplasm to the cell periphery) and myelin-protein expression complete the myelination process.

The cytoplasmic region forms a continuous network of non-compact myelin that consists of Schmidt-Lanterman incisures, paranodal loops and inner- and outer- internodal loops. They express a number of adhesion- and adhesion-like proteins that are involved in axon-Schwann cell interaction as well as proteins involved in establishing adherens junctions between each layer of concentric Schwann cell membrane (Arroyo and Scherer 2000; Menichella et al. 2001). These junctions are termed "autotypic junctions" because unlike

Corresponding Author: Haesun A. Kim, Department of Biological Sciences, Rutgers University, 195 University Ave, Newark, NJ 07102, Phone: 973-353-1454, Fax: 973-353-1007, E-mail: E-mail: haekim@andromeda.rutgers.edu .

¹A.T.C and D.D contributed equally to this work

²Present address: Department of Neurological Surgery, Neurological Institute of New Jersey, The University of Medicine & Dentistry of New Jersey, Newark, NJ 07103

typical adherens junctions that are formed between two epithelial cells, they are formed within a single Schwann cell. One of the major components of the autotypic junction is E-cadherin, a type-I transmembrane protein of the classic cadherin family (Fannon et al. 1995). In epithelial cells, cadherins mediate calciumdependent adhesion between two cells as a component of adherens junction. The extracellular domain of cadherins interact homophilically with cadherins of opposing cells whereas the cytoplasmic domain connects with the cytoskeleton through a core complex formation with members of the catenin family including β -catenin and p120 catenin (Wheelock and Johnson 2003; Yap et al. 1997). In myelinating Schwann cells, E-cadherin containing autotypic junctions play an essential role in stabilizing Schmidt-Lanterman incisures through recruitment of p120 catenin to E-cadherin (Tricaud et al. 2005). E-cadherin is also required for the proper

E-cadherin expression in Schwann cell lineage is under strong developmental control. During development, E-cadherin expression is absent in Schwann cell precursors. Instead, the precursors express high levels of N-cadherin, another member of the classical cadherin family (Wanner et al. 2006). N-cadherin function during this stage is thought to involve facilitating axonal growth and compaction by mediating contacts among Schwann cell precursors. Later, N-cadherin starts to disappear as Schwann cell precursors convert to Schwann cells. Disappearance of N-cadherin is followed by the appearance of E-cadherin in neonatal Schwann cells. Later, the E-cadherin expression gradually increases and become restricted to the myelinating Schwann cell lineage (Fannon et al. 1995; Menichella et al. 2001).

The molecular cue that triggers E-cadherin expression, and perhaps at the same time suppresses N-cadherin expression, is unknown. A line of evidences suggests that the cadherin switch in Schwann cells might be triggered by components on the axonal membrane. For example, it has been shown that when axon-Schwann cell contact is disrupted in adult PNS following axonal degeneration, E-cadherin expression disappears from the Schwann cells while N-cadherin expression reappears (Fannon et al. 1995; Thornton et al. 2005). When the contact is reestablished following nerve regeneration, E-cadherin reappears and N-cadherin disappears, recapitulating the developmental regulation of cadherin expression. A recent study has shown that treatment of postnatal Schwann cells with neuregulin-1, an axonal protein, restores N-cadherin expression suggesting that induction of N-cadherin during early Schwann cell development might be regulated by neuregulin-1 on developing axons (Wanner et al. 2006). However, nature of the signal that later suppresses N-cadherin and induces E-cadherin expression is unknown.

Aim of the present study is to define the molecular cue that triggers E-cadherin expression in postnatal Schwann cells. Here we present data showing that the cAMP-dependent protein kinase A pathway plays an essential role in promoting E-cadherin expression. We also show that cAMP-dependent E-cadherin expression is accompanied by downregulation of N-cadherin, suggesting that cAMP-PKA activation might play a role as a developmental signal that triggers cadherin switch in Schwann cells.

Materials and Methods

Antibodies and growth factors

For immunofluorescence staining, monoclonal antibody to E-cadherin (clone 36, BD Transduction Laboratories, Franklin Lakes, NJ) was used at a dilution of 1:200 and chicken polyclonal antibody neurofilament (Covance, Berkeley, CA) was used at 1:2000. For Western blot analysis, E-cadherin antibody was used at 1:3000 and monoclonal antibody to N-cadherin (clone 32, BD Transduction Laboratories) was used at 1:2500. Monoclonal antibody to β -actin (AC-15, Sigma, St. Louis, MO) and GFAP (Sigma, St. Louis, MN) was

used at 1:5000 and 1:1000, respectively. Recombinant SMDF (R&D systems, Minneapolis, MN) and GGF (Cambridge Neuroscience, Norwood, MA) were used at 10 ng/ml. Platelet derived growth factor BB (Millipore, Billerica, MA) was also used at 10 ng/ml.

Culture Media

Primary rat Schwann cells were grown in growth medium composed of Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), 1% glutamine, and 0.1 mg/ml penicillin-streptomycin, neuregulin-1 EGF-domain (10 ng/ml) (R&D systems, Minneapolis, MN) and Forskolin (5 μ M, Sigma, St. Louis MN). A serum-free defined N2 medium was composed of DMEM and F-12 at a 1:1 ratio, supplemented with 5 ng/ml Na selenite, 16 μ g/ml putrescine, 125 ng/ml progesterone, 0.2 mg/ml apotransferrin, 0.8 μ g/ml insulin, and 1% penicillin-streptomycin. Dorsal root ganglion neurons were maintained in Neurobasal medium (Invitrogen, Carlsbad, CA), supplemented with 2% B27 supplement (Invitrogen), 1% glutamine, 1% penicillin-streptomycin, 0.4% glucose and 25 ng/ml NGF (Millipore, Billerica, MA).

Preparation of Schwann cells

Schwann cells were prepared as described previously (Brockes, 1978). Briefly, sciatic nerves were harvested from postnatal day 1 or 2 rats and enzymatically dissociated by incubation with 1% collagenase prepared in DMEM for thirty minutes at 37 °C followed by incubation in 0.25% Trypsin and 1% Collagenase solution for 30 minutes at 37 °C. Cells were spun down and pellets were resuspended in 10% FBS in DMEM, and then plated on two 60 mm culture plates in the same medium. The following day the media was changed to 10% FBS medium containing 10 μ M cytosine arabinoside (AraC) to kill off proliferating fibroblasts. Three days later, in order to remove residual fibroblasts, cells are gently trypsinized, pelleted and incubated with anti-Thy1 antibody (AbD Serotec, Raleigh, NC) prepared in DMEM at a dilution of 1:1000. This was followed by incubation in rabbit complement (Jackson Immuno, West Grove, PA) for the same length of time. Schwann cells were then plated on poly-L-Lysine-coated 100 mm culture plates and maintained in Schwann cell growth medium.

Preparation of Purified rat DRG neuron cultures

Dorsal root ganglion were removed from rat embryos between E14.5-E16.5 and dissociated in 0.25% Trypsin for 30 minutes at 37 °C. The dissociated DRG were plated on 12 mm collagen-coated glass coverslips (1 DRG/coverslip) in DMEM and 10% FBS supplemented with 25 ng/ml of NGF in a 120 μ l droplet. To remove proliferating non-neuronal cells, the following day, cultures were flooded in Neurobasal medium and B27 supplement mixture containing 15 μ M Fluorodeoxyuridine (FUDR). Two days later FUDR was removed from the medium and cultures were maintained in Neurobasal medium with the supplements for two days before starting a new cycle of FUDR treatment. Cycling in FUDR was continued for 10 days until all non-neuronal cells were removed.

Schwann cell-DRG co-cultures

Prior to seeding onto DRG neurons, Schwann cells were maintained in serum-free N2 medium for three days. The growth factor-deprived Schwann cells were trypsinized and plated onto DRG neurons at a density of 200,000 cells/coverslip in DMEM supplemented with 10% FBS and NGF (25 ng/ml). In control cultures, Schwann cells were plated onto coverslips in the absence of neurons (Schwann cell-only), or neurons were maintained in the absence of Schwann cells (neuron-only). E-cadherin expression was assessed on day 1, 3, 7 and 9 following plating of the Schwann cells. For cAMP-PKA inhibition in co-cultures, Schwann cells were plated onto neurons as above and 24 hours later, 10 μ M H-89

(Calbiochem, San Diego, CA) was added to the culture medium. Three and six days later, cultures were harvested and E-cadherin expression was assessed by Western blot analysis. Alternatively, trypsinized Schwann cells (200,000 cells) were incubated in 1 ml of DMEM + 10% FBS supplemented with cell permeable myristoylated PKI 14-21 Amide (100 μ M) (Calbiochem, San Diego, CA) for 40 minutes then washed twice in DMEM + 10% FBS. The cells were then plated onto DRG neurons as above. Three days later, E-cadherin expression was assessed by Western blot analysis.

Schwann cell proliferation assay

Schwann cells were plated onto poly-L-lysine coated glass coverslips (40,000 cells/coverslip) in DMEM + 10% FBS. Sixteen to twenty hours later, cells were treated with GGF (10 ng/ml), Forskolin (5 μ M), or in combination in the presence or absence of H-89 (5 μ M) or myristoylated PKA (20 μ M). Sixteen-hours later, bromo-deoxy-uridine (BrdU) (1 μ M) was added to each coverslip. Twenty-four hours later, cells were fixed in cold methanol for 10 minutes, rehydrated in PBS for 3 minutes and then treated with 2N HCl for 15 minutes at 37 °C. Cells were washed 3 times in 0.1 M borate buffer (pH8.5) over a 10 minute period then washed 3 times in PBS in the same manner. Cells were then incubated in blocking solution (5% normal goat serum supplemented with 0.2% Triton X 100) for 30 minutes and incubated with monoclonal BrdU antibody (Sigma, St. Louis MN) prepared in blocking solution for 1 hour at room temperature. Alexa-conjugated-goat anti mouse secondary antibody was added for 1 hour and before mounting, cells were incubated with DAPI for 1 minute to visualize nuclei.

SDS PAGE and Western blotting

Cells were lysed in lysis buffer (20 mM Tris pH 7.4, 1% NP-40, 10% glycerol, 2.5 mM EGTA, 2.5 mM EDTA, 1 mM sodium ortho-vanadate, 1 mM sodium fluoride, 1 mM PMSF, 10 μ g/ml aprotinin and 20 μ M leupeptin) and the cell lysates were centrifuged at 14,000 rpm at 4 °C for 15 minutes and supernatants were collected. The protein concentrations were measured using BCA Protein Assay Kit (Pierce, Rockford, IL) according to manufacturers' instructions. Samples (20-100 μ g) were fractionated by SDS PAGE and transferred onto PDVF membrane. For Western blot analysis, the membranes were incubated in blocking solution (5% non-fat dried milk in TBS) for one hour followed by incubation with appropriate primary antibodies prepared in TBST (TBS + 0.5% tween + 5% BSA) overnight at 4 °C. The next day, the membranes were washed 3 times for 10 minutes each in TBST then incubated in secondary antibody prepared in blocking solution with 0.5% tween for 1 hour. The blots were then incubated with ECL Western Blotting substrate for 1 minute and exposed on X-ray films.

Immunofluorescence staining

Co-cultures were fixed in 4% paraformaldehyde prepared in PBS for 25 minutes and permeabilized in methanol for 10 minutes at -20 °C. After rehydrating in PBS, the cultures were incubated in blocking solution (10% normal goat serum + 0.3% Triton X-100) for 1 hour followed by incubation with primary antibodies overnight at 4 °C. Next day, after washing in PBS, the cultures were incubated with the appropriate secondary antibodies for 45 minutes at room temperature. This was followed by incubation with DAPI for 1 minute to visualize nuclei. Coverslips were then mounted onto glass slides using Fluoromount G. Images were acquired using the LSM 510 confocal microscope and analyzed using LSM software (Zeiss, Thornwood, NY).

Quantitative real-time PCR

The real-time PCR technique was used to detect the expression of E-cadherin and the N-cadherin. Total RNA was extracted from cultured Schwann cells or Schwann cell-DRG co-cultures. cDNA was amplified from 1 µg of RNA in the presence of 200 units of Moloney murine leukemia virus-RT, 40 units of Rnasin, 1 µg of random primers, 0.5 mM dNTPs, 3 µg of bovine serum albumin, and 1X Moloney murine leukemia virus reaction buffer (Promega, Madison, WI) in a total volume of 30 µl at 42 °C for 1 hr. cDNA was diluted 10 times for real-time PCR. The PCR mixture consists of 2 µl diluted cDNA, 5 µl of SYBR green-containing PCR master mixture (2X), and 150 µM of each primer in a total volume of 10 µl. The specific primers for real-time PCR were designed by using the primer express™ software from Applied Biosystems (Foster city, CA) and the primer sequences were as follows: E-cadherin sense 5'-TGAAGCCCAGGAAATACACCC-3' and anti-sense 5'-GGATTAAAGGCGTGCACCAAC-3'; N-cadherin sense 5'-AGCCGATGAAGGAACCACATG-3' and anti-sense 5'-TTCTGGCAAGTTGATCGGAGG-3'; GAPDH sense 5'-TTCTTGTGCAGTGCCAGCC-3' and anti-sense 5'-CACCGACCTTCATCTTGT-3'. Real-time PCR was performed using the ABI PRISM 7900HT sequence detection system (Applied Biosystems). The parameters for the PCR were as follows: 95 °C for 15 s and 60 °C for 1 min for 40 cycles followed by a melting point determination. If the amplification of the cDNA is specific it results in a single peak. GAPDH was used as a reference gene and was run in parallel with the samples. A standard curve was generated for each pair of the primers. The expression level for each gene is shown as cycle numbers, which were converted into arbitrary units of DNA using the standard curve. The results were normalized to the mRNA levels of the housekeeping gene GAPDH in the same sample.

Results

Cadherin switch in postnatal peripheral nerves

Developmental regulation of cadherin expression in peripheral nerve is shown in Figure 1. Sciatic nerve lysates were prepared from postnatal rats at different ages and both E- and N-cadherin expression was assessed by immunoblotting. E-cadherin protein was expressed at a low level at postnatal day 1 (P1) which then gradually increased in later ages. This is in agreement with a previous study of E-cadherin expression in mouse sciatic nerves (Menichella et al. 2001). In peripheral nerves, E-cadherin expression is restricted to Schwann cells and absent from the axons (Fannon et al. 1995; Menichella et al. 2001), thus the increase in E-cadherin level shown in Figure 1 is likely to reflect the change in Schwann cells. Unlike E-cadherin, N-cadherin was expressed at a high level in P1 sciatic nerves followed by a gradual decrease in later ages and was undetectable in P21 nerves. Therefore, expression of E-cadherin and N-cadherin is reciprocally regulated during postnatal development of Schwann cell.

E-cadherin expression in Schwann cells is induced by axonal components

The signal that induces E-cadherin expression in postnatal Schwann cell is unknown. *In vivo*, it has been shown that E-cadherin expression in Schwann cells is lost when the associated axons degenerate following nerve injury. The expression is restored when axons regenerate and reestablish contact with the Schwann cells, suggesting that E-cadherin expression is regulated by components on the axonal membrane (Menichella et al. 2001). To investigate whether a contact with axonal membrane is sufficient to induce E-cadherin expression in Schwann cells, we assessed E-cadherin induction in Schwann cells associated with axons in a Schwann cell-neuron co-culture system. Schwann cells prepared from neonatal rat sciatic nerves were maintained in serum-free medium for three days prior to plating onto dorsal root ganglion (DRG) neurons. At this time, Schwann cells were devoid

of E-cadherin expression (SC lane, Figure 2A). E-cadherin was also absent from DRG neurons (DRG lane). When Schwann cells were seeded onto DRG neurons, there was a gradual increase in E-cadherin expression, indicating that axonal components triggered E-cadherin expression in the Schwann cells. To determine whether the expression was also regulated at the mRNA level, we conducted real-time PCR analysis on total RNA collected from the co-cultures (Figure 2B). As seen with the protein, E-cadherin mRNA was mostly absent from Schwann cell-only and neuron-only cultures and was induced only when the Schwann cells were plated onto neurons.

Peripheral neurons do not express E-cadherin, hence the expression seen in the co-culture is likely to reflect induction in the Schwann cells (Fannon et al. 1995; Menichella et al. 2001). To confirm this, we performed double-immunofluorescence analysis on Schwann cell-only or 3-day and 7-day co-cultures using antibodies to E-cadherin and neurofilament, a neuronal marker (Figure 2C). E-cadherin immunoreactivity was not detectable in Schwann cells-only cultures, in the absence of DRG neurons. When plated onto neurons, there was a gradual increase in the protein expression specific to the Schwann cells. Axons visualized by neurofilament expression were devoid of E-cadherin expression.

Cadherins are initially synthesized as inactive propeptide precursors, which are processed post-translationally by removal of the propeptide fragment and inserted into the membrane as biologically active mature protein (Grunwald 1993). To determine whether E-cadherin in the axon-associated Schwann cells is expressed as the membrane-bound mature form, we conducted confocal immunocytochemical analysis on 6-day co-cultures to determine the intracellular localization of E-cadherin in Schwann cells (Figure 3). Schwann cell-DRG co-cultures were fixed and immunostained for E-cadherin, neurofilament and glial fibrillary acidic protein (GFAP), a Schwann cell specific cytoskeletal protein. Most of the E-cadherin expression was seen at the cell periphery and did not co-localize with the cytoplasmic GFAP, indicating the cell surface expression of the mature protein. A small amount of E-cadherin expression was detected within the cytoplasm, which is likely to represent the precursor form of protein being processed within the cell. The presence of the precursor protein was also detected by Western blot analysis as the slower migrating bands shown in Figure 2A: in 7- and 9- day co-cultures, most of the E-cadherin was present as the mature form. The confocal images also showed that the E-cadherin⁺ Schwann cell processes were aligned along the length of the axon (neurofilament⁺) indicating a direct contact formation between the two cell types.

Taken together, these results suggest that axonal components trigger E-cadherin expression in Schwann cells, possibly by a direct contact between the two cell types, and the expression is regulated both at the mRNA and the protein levels.

Elevation of cAMP in Schwann cells mimics axonal effect on E-cadherin expression

What is the axonal component that triggers E-cadherin expression in Schwann cells? Various growth factors are expressed on the axonal membrane of peripheral neurons with the corresponding receptors expressed on Schwann cell surface. Among these, members of the neuregulin-1 growth factor family have been shown to mediate signaling between peripheral axons and Schwann cells (Garatt et al. 2000; Nave and Salzer 2006). Elevation of cAMP has also been shown to mediate axonal signaling in Schwann cells (Mirsky and Jessen 2001). Therefore, we investigated whether neuregulins or cAMP might play a role in regulating E-cadherin induction in Schwann cells. We also tested the effect of platelet derived growth factor (PDGF) since its function had been implicated in the development and in maintenance of peripheral nerves (Eccleston et al. 1993; Hardy et al. 1992). To assess the role of neuregulin-1, we used two of the isoforms, glial growth factor (GGF), a Type-II neuregulin-1, and sensory and motor neuron derived factor (SMDF), a Type-III neuregulin-1

as these isoforms have been shown to play a key role in regulating Schwann cell development (Garratt et al. 2000; Nave and Salzer 2006). Forskolin, an adenylyl cyclase activator, was used to assess a role of cAMP-dependent pathway. Growth factor-deprived neonatal rat Schwann cells were treated with Forskolin, GGF, SMDF or PDGF individually or in combination with Forskolin and the growth factors. Forty-eight hours later E-cadherin amount was determined from the cell lysates by immunoblotting (Figure 4A). E-cadherin expression was absent from control cells without any treatment (NT lane). Addition of GGF, SMDF or PDGF had minimal or no effect on E-cadherin expression. When cells were treated with Forskolin, however, there was a robust increase in E-cadherin expression. A combined treatment of Forskolin with GGF, SMDF or PDGF did not result in a significant change in Forskolin induced E-cadherin expression. Therefore, Forskolin treatment alone is sufficient to mimic the axonal effect by inducing E-cadherin expression in Schwann cells.

We further analyzed the mechanism of Forskolin-induced E-cadherin expression. To determine the expression kinetics, Schwann cells were treated with Forskolin and E-cadherin expression was determined at various hours following the treatment (Figure 4B). An increase in E-cadherin protein was detected as early as 24 hours following Forskolin treatment and the level remained high at later time points. The Forskolin effect was also seen at the mRNA level with a significant induction of E-cadherin mRNA at 24 hours (Figure 4C), similar to the axonal function described above. Treatment with dibutyryl cAMP (dbcAMP), a cell permeable cAMP analogue, also induced E-cadherin expression in a concentration dependent manner (Figure 4D) suggesting the involvement of cAMP-dependent pathway in inducing E-cadherin expression in Schwann cells.

The effect of cAMP elevation on E-cadherin induction is mediated by the cAMP-dependent protein kinase A

H-89 has been widely used to block cAMP-PKA activity in Schwann cells (Kim et al. 1997a; Muja et al. 2007; Xu et al. 2002), however, it can also block activities of other kinases (Davies et al. 2000). Elevation of cAMP and the subsequent activation of cAMP-PKA in Schwann cells has been shown to synergize with neuregulin-1 to induce Schwann cell proliferation (Kim et al. 1997a; Rahmatullah et al. 1998). Therefore, we used neuregulin-induced Schwann cell proliferation as an indirect bioassay to test the specificity of H-89 on cAMP-PKA inhibition. We also used a cAMP-PKA-specific inhibitory peptide PKI (myristoylated-PKI) as a control to assess the specificity of H-89. As seen in Figure 4E, Forskolin treatment greatly enhanced the mitogenic activity of the neuregulin. As expected, treatment with PKI abrogated the Forskolin effect suggesting the involvement of cAMP PKA. A similar inhibitory effect was seen in cultures treated with H-89 indicating that the H-89 effect was mediated by its inhibition of the cAMP-PKA.

Next, we used H-89 to determine whether Forskolin-induced E-cadherin induction was mediated by the cAMP-PKA pathway. Schwann cells were pre-incubated with H-89 for 30 minutes then treated with Forskolin. Forty-eight hours later, the E-cadherin mRNA levels were assessed by real-time PCR (Figure 4F). There was a dose-dependent inhibition of E-cadherin mRNA induction by H-89 suggesting that the Forskolin function was mediated through the activation of cAMP-PKA.

Removal of cAMP mimics the effect of axon-loss on Schwann cells by downregulating E-cadherin expression

In vivo, injury induced axonal degeneration results in loss of E-cadherin expression in distal Schwann cells (Menichella et al. 2001), indicating that continuous axonal contact is required to maintain E-cadherin expression. Since cAMP was able to mimic the axonal effect that induces E-cadherin expression, we asked whether a continuous presence of cAMP is needed

to maintain the protein level. In other words, whether removal of cAMP elevation would result in downregulation of E-cadherin in Schwann cells. To test this, Schwann cells were treated with Forskolin for 48 hours to induce E-cadherin expression. Once induced, Forskolin was withdrawn from the culture medium and Schwann cells were maintained in the absence of Forskolin for various hours. E-cadherin protein levels were determined from the cell lysates prepared at 12, 24, 36 and 48 hours following Forskolin removal (Figure 5A). Initial Forskolin treatment resulted in a robust E-cadherin induction in Schwann cells (Forsk lane). Following Forskolin removal, there was a gradual decrease in the amount of E-cadherin protein level suggesting degradation of the protein. We also determined the effect of Forskolin removal on E-cadherin mRNA levels by real-time PCR (Figure 5B). The effect on mRNA was more dramatic as compared to the protein; within 6 hours of removing Forskolin, E-cadherin mRNA level was decreased close to the basal level. This result suggests that removal of Forskolin results in E-cadherin downregulation by decreasing the amount of protein as well as the mRNA. As a result, continuous cAMP elevation is required to maintain E-cadherin expression level in Schwann cells.

Contact between Schwann cell membranes promotes E-cadherin expression in a cAMP dependent manner

During myelination, E-cadherin levels increase and the expression becomes localized at the autotypic junctions (Fannon et al. 1995; Menichella et al. 2001). Since autotypic junctions are formed when a concentric layer of Schwann cell membrane comes into contact with the previous layer, it is predicted that contact between Schwann cell membranes should regulate E-cadherin expression. To investigate this, Schwann cells were plated in 60 mm culture plates (28.26 cm²) at densities ranging from 0.65×10⁶ cells/28.26 cm² (low density, minimal membrane contact) to 3.6×10⁶ cells/28.26 cm² (high density, maximal membrane contact), in the presence or absence of Forskolin. Two days later, E-cadherin expression was assessed by immunoblotting (Figure 6). In cultures without Forskolin treatment (-Forskolin), there was no detectable level of E-cadherin regardless of the cell density. In the presence of Forskolin (+Forskolin), however, there was a density-dependent increase in E-cadherin amount. This result suggests that contact between Schwann cell membranes promotes E-cadherin expression in a manner that is dependent on cAMP elevation.

Axon-induced E-cadherin expression is blocked by inhibition of cAMP-PKA pathway

So far, we have observed that elevation of cAMP in Schwann cells mimics the role of axons that induces E-cadherin expression. In addition, removal of cAMP mimics the effect of axonal-loss by downregulating E-cadherin expression. These results lead to a prediction that axon-induced E-cadherin regulation is mediated by activation of the cAMP-dependent pathway in the associated Schwann cells. To address this, we investigated whether inhibition of the cAMP-PKA pathway in Schwann cell-neuron co-cultures could block axon-induced E-cadherin expression in the Schwann cells. Growth factor-deprived Schwann cells were seeded onto DRG neurons and allowed to establish their contacts with the axons. Twenty-four hours later, co-cultures were treated with H-89 at a final concentration of 10 μM, a concentration that was sufficient to block Forskolin-mediated E-cadherin mRNA induction in Schwann cells (Figure 4F). Control cultures were treated with solvent dimethyl sulfoxide (DMSO). Three and six days later, E-cadherin protein levels were determined from the co-culture cell lysates (Figure 7A). No detectable amount of E-cadherin was seen in control Schwann cell-only (SC) or neuron-only (DRG) cultures. In co-cultures treated with DMSO, there was an increase in E-cadherin expression. In cultures treated with H-89, the presence of axons failed to induce E-cadherin expression. It has been shown previously that inhibition of cAMP-PKA by H-89 treatment blocks Schwann cell proliferation in the co-culture system (Kim et al. 1997b). Since it was possible that the reduced E-cadherin levels could have been due to a decrease in Schwann cell number by H-89 treatment, we determined the levels of

Schwann cell-specific protein glial fibrillary acidic protein (GFAP) in the lysates. The GFAP level remained constant across the samples indicating that there was no significant decrease in the Schwann cell number in H-89 treated culture during the experimental periods.

Cyclic AMP-PKA has been shown to play an important role in supporting neuronal survival. To rule out the possible effect of cAMP-PKA inhibition on the DRG neurons, we used an alternative approach to inhibit cAMP-PKA in a Schwann cell-specific manner. Prior to seeding on the neurons, Schwann cells were pre-incubated with cell permeable, myristoylated PKI for 40 minutes in order to introduce the peptide into the cells. The Schwann cells were then washed thoroughly and plated onto DRG neurons and maintained in culture medium in the absence of PKI. Three days later, E-cadherin expression was assessed by immunoblotting. As seen in Figure 7B, the axon-induced E-cadherin expression was greatly reduced in Schwann cells pre-incubated with PKI. Since DRG neurons were never exposed to the peptide, this result suggests that axon-induced E-cadherin expression is due to cAMP-PKA activity in Schwann cells, but not in the neurons. Altogether, these results suggest that activation of cAMP-PKA is required for axonal function that induces E-cadherin expression in Schwann cells.

Cyclic AMP-PKA suppresses N-cadherin expression while promoting E-cadherin expression in Schwann cells: a possible role in mediating cadherin switch?

In postnatal peripheral nerves, an increase in E-cadherin expression in the Schwann cell is accompanied by a decrease in N-cadherin expression (Figure 1). Our results on cAMP-induced E-cadherin expression therefore, raise the possibility that the cAMP-dependent pathway plays a role in mediating the cadherin switch by suppressing N-cadherin expression in Schwann cells. It has been shown previously that cultured Schwann cells grown in the absence of axonal contact express a high level of N-cadherin but not E-cadherin (Wanner and Wood 2002). Therefore, we investigated whether Forskolin treatment on cultured Schwann cells could downregulate the N-cadherin expression (Figure 8A). In control cultures without Forskolin treatment, there was a significant level of N-cadherin, in agreement with the previous study. When Schwann cells were treated with Forskolin, there was a drastic decrease in N-cadherin levels 48 hours later. Pretreatment of cultures with PKI reversed the cAMP effect, suggesting that the inhibitory effect on N-cadherin expression was mediated by the cAMP-PKA.

The opposing effects of cAMP-PKA on E-cadherin and N-cadherin expression suggest that cAMP-PKA might function as the signal that initiates the cadherin switch in postnatal Schwann cells. To address this, Schwann cells were treated with Forskolin for various hours and the levels of E-cadherin and N-cadherin mRNA were determined simultaneously within the same cell population by real-time PCR (Figure 8B). In the absence of Forskolin treatment, N-cadherin mRNA appeared to be the predominant cadherin mRNA expressed in the cells while E-cadherin mRNA was almost absent. Following Forskolin treatment, there was a gradual increase in the E-cadherin mRNA while N-cadherin mRNA began to decrease, indicating the cadherin switch. By 24 hours, E-cadherin became predominant over N-cadherin in the Schwann cells. Taken together, our results suggest that elevation of cAMP reciprocally regulates cadherin expression in Schwann cells: it suppresses N-cadherin while promoting E-cadherin expression. Therefore, cAMP elevation might function as a signal that mediates cadherin switch during the postnatal development of Schwann cells.

Discussion

In this study, we have sought to identify molecular cues that trigger E-cadherin expression in postnatal Schwann cells. We report that the expression is mediated by an axonal component

that activates the cAMP-PKA pathway in Schwann cells. This is evident by the findings that inhibition of cAMP-PKA blocks axon-mediated E-cadherin expression in Schwann cells and elevation of cAMP is sufficient to trigger E-cadherin induction in the absence of the axons. Furthermore, we show that E-cadherin promoting function of cAMP is accompanied by a function that suppresses N-cadherin expression, suggesting that cAMP-PKA might play a role in mediating cadherin switch in Schwann cells.

Cadherin switching is an integral part of embryonic development (Gumbiner 2005; Wheelock and Johnson 2003). In a situation that requires dynamic cellular rearrangement, tissue integrity must be disrupted so that cells can migrate from their original position. For example, when epithelial cells change their relative position within a tissue, they convert to migratory fibroblastic cells, a phenomenon referred to as the epithelium-to-mesenchyme transition (EMT). The EMT is often mediated by downregulation of E-cadherin that disrupts epithelial polarity, which is followed by upregulation of N-cadherin that increases cell motility (Affolter et al. 2003; Gould and Mattingly 1990). In the PNS, loss of N-cadherin expression and gain of E-cadherin expression during Schwann cell development is reminiscent of the cadherin switch during EMT, only in reverse: N-cadherin expression is associated with migratory Schwann cell precursors (Wanner et al. 2006) whereas E-cadherin expression is enriched in differentiated myelinating Schwann cells (Fannon et al. 1995). Therefore, the cadherin switch in the PNS might play a crucial role by facilitating conversion of migratory embryonic Schwann cells (N-cadherin positive, E-cadherin negative) into non-migratory, polarized myelinating Schwann cells (N-cadherin negative, E-cadherin positive).

Molecular mechanisms that regulate cadherin switch in Schwann cells have not been extensively investigated. A recent study has shown that downregulation of N-cadherin in postnatal Schwann cells can be reversed by treatment with neuregulin-1 which results in re-expression of the protein on the cell surface (Wanner et al. 2006). Neuregulin-1 is expressed on axonal membrane of the PNS neurons and has been shown to play multiple roles in regulating Schwann cell development through activation of the receptor, erbB2 and erbB3, expressed on the Schwann cell surface (Garratt et al. 2000). This raises a possibility that neuregulin-erbB signaling might be involved in the initial induction of N-cadherin expression in Schwann cell precursors. However, it is unlikely that neuregulin-1 is also responsible for the subsequent N-cadherin suppression and E-cadherin induction since neuregulin and erbB receptor expression persists throughout embryonic and postnatal PNS. Furthermore, we have shown in the present study that neuregulin-1 fails to induce E-cadherin expression in Schwann cells.

Here we show that cAMP-PKA activation fulfills the role as a signal that mediates cadherin switch in Schwann cells by simultaneously suppressing N-cadherin expression and inducing E-cadherin expression. Cyclic AMP has long been considered as an important developmental signal that mediates axon-to-Schwann cell communication. For example, inhibition of cAMP-dependent PKA blocks axon-induced Schwann cell proliferation and myelination (Howe et al. 2001; Kim et al. 1997b). Elevation of intracellular cAMP in Schwann cells mimics axon-contact by promoting Schwann cell proliferation, differentiation and myelin-gene expression (Eccleston 1992; Lemke et al. 1988; Morgan et al. 1991). Therefore, the cadherin switch in Schwann cells might be another example of the cAMP-dependent function of the axons that regulates Schwann cell development.

Although, the axonal signal that regulates cAMP levels in the associated Schwann cell is unknown, it has been suggested that endogenous cAMP levels of peripheral nerves is under developmental regulation. This is evident by previous studies, which have shown that cAMP in rat sciatic nerve increases during nerve regeneration and decreases following nerve injury

(Poduslo et al. 1995; Walikonis et al. 1998). Furthermore, it has been shown that there is a high endogenous cAMP level in myelinated nerve, but not in non-myelinated nerve, hence associating cAMP elevation with building of the myelin sheath (Poduslo et al. 1995). Therefore, developmental regulation of endogenous cAMP might be associated with the cAMP-dependent axonal function that regulates postnatal development of myelinating Schwann cell lineage in the PNS.

Our data show that cAMP regulates E-cadherin expression both at the protein and the mRNA levels. The mechanism by which cAMP stimulates E-cadherin transcription in Schwann cell is unclear. In thyroid cells, it has been shown that activation of cAMP-PKA induces E-cadherin protein and mRNA by a mechanism that requires protein synthesis, suggesting that the expression is regulated indirectly through induction of a protein or a transcription factor (Brabant et al. 1995). A recent study has identified a cAMP-responsive element (CRE) sequence in the promoter region of E-cadherin suggesting a cAMP-dependent induction of E-cadherin expression (Mauro et al. 2007). Alternatively, cAMP might function to suppress transcription factors that are known to repress E-cadherin expression (Batlle et al. 2000; Cano et al. 2000). Another mechanism by which cAMP maintains E-cadherin expression on the Schwann cell surface might involve stabilizing the protein by inhibiting E-cadherin degradation. This is supported by our data showing that a continuous increase in cAMP within the Schwann cell is required for maintaining E-cadherin expression and removal of Forskolin results in rapid degradation of E-cadherin product. Previous work with thymocytes has demonstrated that activation of the cAMP-PKA prevents E-cadherin turnover by inhibiting cell surface degradation and internalization (Larsson et al. 2004).

We further show that cAMP-mediated upregulation of E-cadherin is accompanied by downregulation of N-cadherin protein as well as the mRNA, indicating transcriptional regulation of N-cadherin expression. In ovarian epithelial cells, activation of cAMP-PKA results in downregulation of N-cadherin expression through a mechanism that involves phosphorylation of CREB (Pon et al. 2005). N-cadherin promoter also contains a probable CRE, making it possible that N-cadherin transcriptional suppression might be mediated by cAMP-PKA-dependent phosphorylation of CREB. An alternative way for facilitating N-cadherin decrease is by accelerating its turnover by stimulating the protein degradation. A similar mechanism has been demonstrated in an epithelial cell line in which cAMP induces degradation of N-cadherin via an ubiquitin-proteasome pathway (Pon et al. 2005).

What role does cadherin switch play in regulating postnatal Schwann cell development? As Schwann cells cease their proliferation in neonatal nerves, they begin the differentiation process by building intimate relationships with the associated axons. Non-myelinating Schwann cells begin to segregate and ensheath a group of small diameter axons. Large diameter axons, destined to become myelinated, become individually wrapped by single myelinating Schwann cells, establishing a unique one-to-one Schwann cell-to-axon relationship. Because N-cadherin has been shown to play a role in enforcing glial-to-glial interaction promoting extensive glial cell contacts, downregulation of the protein in postnatal Schwann cells prior to differentiation might be an essential step to loosen up the glial cell contacts for formation of proper axon-Schwann cell units. Subsequent E-cadherin expression might facilitate Schwann cell differentiation (myelination) by organizing and polarizing membrane proteins and junctional components as seen in other cell types. E-cadherin also participates in forming autotypic junctions that provide stability to structural components of myelinating Schwann cells.

In conclusion, activation of the cAMP-dependent pathway in postnatal Schwann cell serves as a developmental signal that mediates cadherin switch. The factor that triggers cAMP

elevation in Schwann cells is likely to be axonal as axon-contact mediated E-cadherin expression is blocked by inhibiting cAMP-PKA activation. Cyclic-AMP-mediated suppression of N-cadherin and induction of E-cadherin therefore is likely to play an important role in regulating postnatal development of Schwann cell.

Acknowledgments

We are grateful for Dr. Charles D. Stiles for his support for the study. This work was supported by NIH grant RO1-NS45939-01 to C.D.S and grants from New Jersey Commission on Spinal Cord Research and New Jersey Commission on Brain Injury Research to H.A.K

References

- Affolter M, Bellusci S, Itoh N, Shilo B, Thiery JP, Werb Z. Tube or not tube: remodeling epithelial tissues by branching morphogenesis. *Dev Cell*. 2003; 4:11–18. [PubMed: 12530959]
- Arroyo EJ, Scherer SS. On the molecular architecture of myelinated fibers. *Histochem Cell Biol*. 2000; 113:1–18. [PubMed: 10664064]
- Battle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia De Herreros A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. *Nat Cell Biol*. 2000; 2:84–89. [PubMed: 10655587]
- Brabant G, Hoang-Vu C, Behrends J, Cetin Y, Potter E, Dumont JE, Maenhaut C. Regulation of the cell-cell adhesion protein, E-cadherin, in dog and human thyrocytes in vitro. *Endocrinology*. 1995; 136:3113–3119. [PubMed: 7789339]
- Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. *Nat Cell Biol*. 2000; 2:76–83. [PubMed: 10655586]
- Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. *Biochem J*. 2000; 351:95–105. [PubMed: 10998351]
- Eccleston PA. Regulation of Schwann cell proliferation: mechanisms involved in peripheral nerve development. *Exp Cell Res*. 1992; 199:1–9. [PubMed: 1735450]
- Eccleston PA, Funa K, Heldin CH. Expression of platelet-derived growth factor (PDGF) and PDGF alpha- and beta-receptors in the peripheral nervous system: an analysis of sciatic nerve and dorsal root ganglia. *Dev Biol*. 1993; 155:459–470. [PubMed: 8432400]
- Fannon AM, Sherman DL, Ilyina-Gragerova G, Brophy PJ, Friedrich VL Jr. Colman DR. Novel E-cadherin-mediated adhesion in peripheral nerve: Schwann cell architecture is stabilized by autotypic adherens junctions. *J Cell Biol*. 1995; 129:189–202. [PubMed: 7698985]
- Garratt AN, Britsch S, Birchmeier C. Neuregulin, a factor with many functions in the life of a schwann cell. *Bioessays*. 2000; 22:987–996. [PubMed: 11056475]
- Gould RM, Mattingly G. Regional localization of RNA and protein metabolism in Schwann cells in vivo. *Journal of Neurocytology*. 1990; 19:285–301. [PubMed: 1697335]
- Grunwald GB. The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules. *Curr Opin Cell Biol*. 1993; 5:797–805. [PubMed: 8240823]
- Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. *Nat Rev Mol Cell Biol*. 2005; 6:622–634. [PubMed: 16025097]
- Hardy M, Reddy UR, Pleasure D. Platelet-derived growth factor and regulation of Schwann cell proliferation in vivo. *Journal of Neuroscience Research*. 1992; 31:254–262. [PubMed: 1374130]
- Howe CL, Valletta JS, Rusnak AS, Mobley WC. NGF signaling from clathrin-coated vesicles: evidence that signaling endosomes serve as a platform for the Ras-MAPK pathway. *Neuron*. 2001; 32:801–814. [PubMed: 11738027]
- Kim HA, DeClue JE, Ratner N. cAMP-dependent protein kinase A is required for Schwann cell growth: interactions between the cAMP and neuregulin/tyrosine kinase pathways. *J Neurosci Res*. 1997a; 49:236–247. [PubMed: 9272646]

- Kim HA, DeClue JE, Ratner N. cAMP-dependent protein kinase A is required for Schwann cell growth: interactions between the cAMP and neuregulin/tyrosine kinase pathways. *Journal of Neuroscience Research*. 1997b; 49:236–247. [PubMed: 9272646]
- Larsson F, Fagman H, Nilsson M. TSH receptor signaling via cyclic AMP inhibits cell surface degradation and internalization of E-cadherin in pig thyroid epithelium. *Cell Mol Life Sci*. 2004; 61:1834–1842. [PubMed: 15241559]
- Lemke G, Lamar E, Patterson J. Isolation and analysis of the gene encoding peripheral myelin protein zero. *Neuron*. 1988; 1:73–83. [PubMed: 2483091]
- Mauro L, Catalano S, Bossi G, Pellegrino M, Barone I, Morales S, Giordano C, Bartella V, Casaburi I, Ando S. Evidences that leptin up-regulates E-cadherin expression in breast cancer: effects on tumor growth and progression. *Cancer Res*. 2007; 67:3412–3421. [PubMed: 17409452]
- Menichella DM, Arroyo EJ, Awatramani R, Xu T, Baron P, Vallat JM, Balsamo J, Lilien J, Scarlato G, Kamholz J. Protein zero is necessary for E-cadherin-mediated adherens junction formation in Schwann cells. *Mol Cell Neurosci*. 2001; 18:606–618. others. [PubMed: 11749037]
- Mirsky, R.; Jessen, KR. Embryonic and early postnatal development of Schwann cells. In: Jessen, KR.; Richardson, WD., editors. *Glial cell development*. Oxford university press; Oxford: 2001. p. 1-20.
- Morgan L, Jessen KR, Mirsky R. The effects of cAMP on differentiation of cultured Schwann cells: progression from an early phenotype (04+) to a myelin phenotype (P0+, GFAP-, N-CAM-, NGF-receptor-) depends on growth inhibition. *J Cell Biol*. 1991; 112:457–467. [PubMed: 1704008]
- Muja N, Nelson JK, DeVries GH. Schwann cells express IP prostanoid receptors coupled to an elevation in intracellular cyclic AMP. *J Neurosci Res*. 2007; 85:1159–1169. [PubMed: 17335081]
- Nave KA, Salzer JL. Axonal regulation of myelination by neuregulin 1. *Curr Opin Neurobiol*. 2006; 16:492–500. [PubMed: 16962312]
- Perrin-Tricaud C, Rutishauser U, Tricaud N. P120 catenin is required for thickening of Schwann cell myelin. *Mol Cell Neurosci*. 2007; 35:120–129. [PubMed: 17382558]
- Poduslo JF, Walikonis RS, Domec MC, Berg CT, Holtz-Heppelmann CJ. The second messenger, cyclic AMP, is not sufficient for myelin gene induction in the peripheral nervous system. *J Neurochem*. 1995; 65:149–159. [PubMed: 7540661]
- Pon YL, Auersperg N, Wong AS. Gonadotropins regulate N-cadherin-mediated human ovarian surface epithelial cell survival at both post-translational and transcriptional levels through a cyclic AMP/protein kinase A pathway. *J Biol Chem*. 2005; 280:15438–15448. [PubMed: 15701645]
- Rahmatullah M, Schroering A, Rothblum K, Stahl RC, Urban B, Carey DJ. Synergistic regulation of Schwann cell proliferation by heregulin and forskolin. *Mol Cell Biol*. 1998; 18:6245–6252. [PubMed: 9774641]
- Thornton MR, Mantovani C, Birchall MA, Terenghi G. Quantification of N-CAM and N-cadherin expression in axotomized and crushed rat sciatic nerve. *J Anat*. 2005; 206:69–78. [PubMed: 15679872]
- Tricaud N, Perrin-Tricaud C, Bruses JL, Rutishauser U. Adherens junctions in myelinating Schwann cells stabilize Schmidt-Lanterman incisures via recruitment of p120 catenin to E-cadherin. *J Neurosci*. 2005; 25:3259–3269. [PubMed: 15800180]
- Walikonis RS, Poduslo JF, Domec MC, Berg CT, Holtz-Heppelmann CJ. Activity of cyclic AMP phosphodiesterases and adenylyl cyclase in peripheral nerve after crush and permanent transection injuries. *J Biol Chem*. 1998; 273:9070–9077. [PubMed: 9535895]
- Wanner IB, Guerra NK, Mahoney J, Kumar A, Wood PM, Mirsky R, Jessen KR. Role of N-cadherin in Schwann cell precursors of growing nerves. *Glia*. 2006; 54:439–459. [PubMed: 16886205]
- Wanner IB, Wood PM. N-cadherin mediates axon-aligned process growth and cell-cell interaction in rat Schwann cells. *J Neurosci*. 2002; 22:4066–4079. [PubMed: 12019326]
- Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. *Annu Rev Cell Dev Biol*. 2003; 19:207–235. [PubMed: 14570569]
- Xu Y, Chiamvimonvat N, Vazquez AE, Akunuru S, Ratner N, Yamoah EN. Gene-targeted deletion of neurofibromin enhances the expression of a transient outward K⁺ current in Schwann cells: a protein kinase A-mediated mechanism. *J Neurosci*. 2002; 22:9194–9202. [PubMed: 12417644]

- Yap AS, Brieher WM, Gumbiner BM. Molecular and functional analysis of cadherin-based adherens junctions. *Annu Rev Cell Dev Biol.* 1997; 13:119–146. [PubMed: 9442870]
- Young P, Boussadia O, Berger P, Leone DP, Charnay P, Kemler R, Suter U. E-cadherin is required for the correct formation of autotypic adherens junctions of the outer mesaxon but not for the integrity of myelinated fibers of peripheral nerves. *Mol Cell Neurosci.* 2002; 21:341–351. [PubMed: 12401452]

Figure 1. Cadherin switch during postnatal development of Schwann cells

Sciatic nerve lysates were prepared at different postnatal days ranging from P1 to P28.

Expression of E-cadherin (E-cad) and N-cadherin (N-cad) was determined by Western blot analysis. In postnatal sciatic nerve, an increase in E-cadherin expression is accompanied by a decrease in N-cadherin expression. A similar amount of actin across the samples indicates an even protein loading.

Figure 2. Axonal components induce E-cadherin expression in postnatal Schwann cells
 (A) Growth factor deprived Schwann cells were plated onto DRG neurons (SC+DRG) and E-cadherin expression was determined at 3 and 7 days following seeding of the Schwann cells by immunoblotting. Schwann cell only (SC) and neuron-only (DRG) cultures were used as controls. (B) E-cadherin mRNA level. Complementary DNA were prepared from total RNA collected from the co-cultures 3- and 6-days after seeding Schwann cells and amplified by real-time PCR with primers specific for E-cadherin. The expression levels of E-cadherin mRNA were normalized to internal house keeping GAPDH mRNA. One representative experiment out of four is shown. (C) Schwann cell specific E-cadherin expression is seen in co-cultures (3 and 7 days) immunostained with antibodies to E-

cadherin (red) and neurofilament (NF, green). No expression is detected in NF-positive neurons or in Schwann cell-only cultures. Individual Schwann cells are visualized by the nuclear DAPI staining.

Figure 3. E-cadherin is expressed on the surface of axon-associated Schwann cells

Confocal images of an axon-associated Schwann cell immunostained for E-cadherin (red), GFAP (green) and neurofilament (blue). The merged image is shown below. Most of the E-cadherin expression is seen on the Schwann cell surface, which is devoid of cytoplasmic GFAP expression. A small amount of the E-cadherin is seen within the cytoplasm, likely representing the unprocessed population of the protein. The Schwann cell is seen in close contact with the axon visualized by the neurofilament (NF) staining. Scale bar: 2 μ m

Figure 4. Cyclic AMP elevation in Schwann cell mimics axon-induced E-cadherin expression

(A) Growth factor-deprived Schwann cells were treated with Forskolin (F) (5 μ M), GGF (10 ng/ml), SMDF (10 ng/ml), PDGF (10 ng/ml), or in combination of Forskolin with the growth factors for 48 hours and E-cadherin expression was determined from the cell lysates by immunoblotting. Actin expression was used as a loading control. (B) and (C) Kinetics of E-cadherin expression in Schwann cells following Forskolin treatment. Schwann cells were treated with Forskolin (5 μ M) and E-cadherin protein and mRNA levels were determined at indicated times by immunoblotting (B) or by real-time PCR (C), respectively. (D) Induction of E-cadherin expression by dbcAMP. Schwann cells were treated with increasing concentrations of dbcAMP as indicated and E-cadherin amount was determined 48 hours

later by immunoblotting. As seen with Forskolin treatment, dbcAMP also induces E-cadherin expression in Schwann cells. (E) H-89 inhibits cAMP-PKA activity in Schwann cells. Schwann cells were treated with GGF or GGF+Forskolin in the presence or absence of H-89 (10 μ M) or PKI (20 μ M). Forty-hours later, the effect of H-89 and PKI on GGF and Forskolin induced Schwann cell proliferation was assessed by determining the percentage of BrdU incorporated Schwann cells. The data represents the mean percentage of BrdU⁺ Schwann cell nuclei ($\pm$ SEM) from 30 fields pooled from two experiments. (F) Forskolin-induced E-cadherin expression is cAMP-PKA dependent. Schwann cells were pretreated with H-89 (5 and 10 μ M) for 30 minutes then treated with Forskolin in the presence of H-89. Forty-eight hours later, levels of E-cadherin mRNA were determined. The expression levels of E-cadherin mRNA were normalized to internal house keeping GAPDH mRNA. One representative experiment out of three is shown.

Figure 5. Forskolin removal mimics the effect of axonal-loss by downregulating E-cadherin Schwann cells were treated with Forskolin (5 μ M) for 48 hours and subsequently Forskolin was removed from the media. (A) Changes in the protein level determined by immunoblotting. (B) Changes in the mRNA level determined by real-time PCR. One representative experiment out of four is presented.

Figure 6. Contact between Schwann cell membranes promotes E-cadherin expression in a cAMP-dependent manner

Schwann cells were plated at different densities in 60 mm culture dishes (28.26 cm^2), in the absence or in the presence of Forskolin ($5 \mu\text{M}$). E-cadherin amount was determined 48 hours later by immunoblotting.

Figure 7. Axon-induced E-cadherin expression in Schwann cell requires activation of the cAMP-PKA pathway

(A) Schwann cells were seeded onto DRG neurons and the next day, cultures were treated with DMSO or H-89 (10 μ M). Cell lysates were prepared at 3- and 6-days following seeding of the Schwann cells. Schwann cell only (SC) and neuron only (DRG) cultures were used as controls. Levels of E-cadherin (E-cad), GFAP and actin were determined by immunoblotting. (B) Schwann cells were preincubated with myristoylated PKI (100 μ M) for 40 minutes then washed twice and plated onto DRG neurons. Three days later, E-cadherin expression was assessed by Western blot analysis.

Figure 8. Forskolin promotes cadherin switch in Schwann cell by suppressing N-cadherin and promoting E-cadherin expression

(A) Schwann cells were treated with Forskolin (5 μM) in the presence or absence of PKI (20 and 50 μM). Forty-eight hours later, N-cadherin (N-cad) expression was determined by immunoblotting. Actin bands show even protein loading. (B) Cyclic AMP induced cadherin switch. Schwann cells were treated with Forskolin for indicated times and E-cadherin (grey bars) and N-cadherin (white bars) mRNA level were determined within the same samples by real-time PCR. The mRNA levels were normalized to internal house keeping GAPDH mRNA. One representative experiment out of four is shown.